AIM VACCINE (06660): mRNA respiratory syncytial virus vaccine approved by the US FDA for clinical trials has significantly higher humoral and cellular immunity than internationally marketed products.

AIM VACCINE (06660) announced that the group is actively advancing the development of vaccine products pipeline in accordance with its established company strategy. Utilizing the advantages of mRNA technology platform and continuous technological innovation, the group is rapidly advancing the research and development of mRNA vaccine products. The mRNA respiratory syncytial virus vaccine has recently obtained clinical trial approval from the U.S. Food and Drug Administration (FDA). This marks the first time that a product from the group has received FDA approval for clinical trials, indicating an important step forward in the group's internationalization strategy. Respiratory syncytial virus is a common respiratory pathogen with high infectivity that is widely prevalent globally. Infections with respiratory syncytial virus are a significant cause of death in infants under one year old and a major factor in respiratory infections leading to death in the elderly. Additionally, individuals who have previously been infected with respiratory syncytial virus are still at risk of reinfection. Currently, there are no approved antiviral drugs specifically targeting respiratory syncytial virus for clinical use worldwide. Vaccination for proactive immune prevention is an effective measure to prevent severe infections from respiratory syncytial virus. The group is one of the earliest companies in China to develop mRNA vaccine products and one of the first domestically to obtain independent patents for mRNA technology. It has a mature mRNA vaccine research and development system. Additionally, the group has established a comprehensive quality management system for mRNA vaccines and a commercial-scale production workshop that meets GMP standards. The mRNA technology platform has been validated through clinical trials on thousands of mRNA vaccine products. The group has now integrated the entire lifecycle process of mRNA vaccine research and development, production, and can quickly achieve industrialization after clinical trials, accelerating the commercialization of vaccine products. As a new heavyweight in the global vaccine market, this product is expected to become a new growth point for the group after its market launch.